Cargando…
Heterologous SARS-CoV-2 vaccine triggers more humoral immune responses among patients with liver cirrhosis
Autores principales: | Kaewdech, Apichat, Pinpathomrat, Nawamin, Chamroonkul, Naichaya, Piratvisuth, Teerha, Sripongpun, Pimsiri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Association for the Study of the Liver. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252369/ http://dx.doi.org/10.1016/S0168-8278(22)00750-4 |
Ejemplares similares
-
Heterologous COVID-19 Vaccination and Booster with mRNA Vaccine Provide Enhanced Immune Response in Patients with Cirrhosis: A Prospective Observational Study
por: Sripongpun, Pimsiri, et al.
Publicado: (2023) -
The efficacy of branched-chain amino acid granules to restore phagocytic activity in cirrhosis patients, a randomized controlled trial
por: Chamroonkul, Naichaya, et al.
Publicado: (2023) -
Validation of the “Six-and-Twelve” Prognostic Score in Transarterial Chemoembolization–Treated Hepatocellular Carcinoma Patients
por: Kaewdech, Apichat, et al.
Publicado: (2021) -
Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up
por: Kaewdech, Apichat, et al.
Publicado: (2022) -
ABO Blood Group Differentials on Survival in Hepatocellular Carcinoma Patients Treated with Chemoembolization
por: Bannangkoon, Kittipitch, et al.
Publicado: (2021)